Shopping Cart 0
Cart Subtotal
USD 0

Merus NV (MRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Merus NV (Merus) is a clinical-stage immuno-oncology company that discovers and develops human bispecific antibody therapeutics for the treatment of cancer. The company's pipeline antibody candidates are intended for the treatment of breast cancer, ovarian cancer, colorectal cancer, acute myeloid leukemia and other solid tumors. Merus develops its product candidates based on its proprietary technology platform biclonics, a bispecific, full length human IgG antibodies. The company has collaboration with Incyte Corporation, to develop preclinical bispecific antibody designed to bind to PD-L1. Merus is headquartered in Utrecht, the Netherlands.

Merus NV (MRUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Merus NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Merus NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Merus NV, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Merus Raises USD55.8 Million in Venture Financing 12

Merus Raises USD46.4 Million in First Tranche of Series C Financing 13

Merus Raises USD 42 Million In Extended Series B Financing 15

Private Equity 17

Biotechnology Value Fund to Invest USD55.8 million in Merus 17

Partnerships 18

Integral Molecular Enters into Agreement with Merus 18

Merus Enters into Research Agreement with Vall d'Hebron Institute of Oncology 19

Merus Enters into Research Agreement with Institute for Research in Biomedicine 20

Merus Enters into Co-Development Agreement with Institut Gustave Roussy 21

Licensing Agreements 22

Ono Pharma Enters into Licensing Agreement with Merus 22

Simcere Pharma to Enter into Licensing Agreement with Merus 23

Incyte Enters into Licensing Agreement with Merus 24

Ono Pharma Exercises Option for Licensing Agreement with with Merus 26

ProBioGen Enters into Licensing Agreement with Merus 27

ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 28

Equity Offering 29

Merus Raises USD80 Million in Private Placement 29

Merus Announces Partial Exercise of Underwriter's Option for IPO for USD61.39 Million 30

Merus NV-Key Competitors 32

Merus NV-Key Employees 33

Merus NV-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Financial Announcements 35

Aug 10, 2018: Merus announces financial results for the second quarter 2018 & mid-year operating results 35

Jul 26, 2018: Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 37

Apr 26, 2018: Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 39

Nov 30, 2017: Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights 42

Sep 19, 2017: Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress 44

Jul 11, 2017: Merus Announces First Quarter 2017 Financial Results And Mid-Year Operating Results 45

Apr 28, 2017: Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments 47

Corporate Communications 49

Sep 27, 2018: Merus strengthens team with key appointments 49

Aug 22, 2018: Merus announces formation of a scientific advisory board 50

Legal and Regulatory 51

Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron 51

Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron 52

Product News 53

04/20/2017: Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Merus NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Merus NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Merus NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Merus NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Merus NV, Deals By Therapy Area, 2012 to YTD 2018 9

Merus NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Merus Raises USD55.8 Million in Venture Financing 12

Merus Raises USD46.4 Million in First Tranche of Series C Financing 13

Merus Raises USD 42 Million In Extended Series B Financing 15

Biotechnology Value Fund to Invest USD55.8 million in Merus 17

Integral Molecular Enters into Agreement with Merus 18

Merus Enters into Research Agreement with Vall d'Hebron Institute of Oncology 19

Merus Enters into Research Agreement with Institute for Research in Biomedicine 20

Merus Enters into Co-Development Agreement with Institut Gustave Roussy 21

Ono Pharma Enters into Licensing Agreement with Merus 22

Simcere Pharma to Enter into Licensing Agreement with Merus 23

Incyte Enters into Licensing Agreement with Merus 24

Ono Pharma Exercises Option for Licensing Agreement with with Merus 26

ProBioGen Enters into Licensing Agreement with Merus 27

ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 28

Merus Raises USD80 Million in Private Placement 29

Merus Announces Partial Exercise of Underwriter's Option for IPO for USD61.39 Million 30

Merus NV, Key Competitors 32

Merus NV, Key Employees 33

Merus NV, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Merus NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.